CAR T cell News and Research

RSS

CAR macrophages can be used to effectively fight solid tumors

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors.

23 Mar 2020

Bioengineers create light-controllable CAR T cells for cancer immunotherapy

Bioengineers at the University of California San Diego have developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer.

19 Feb 2020

UCLA researcher designs ways for immune cells to 'outsmart' solid tumors

Yvonne Chen engineers immune cells to target their most evasive enemy: cancer. New cancer immunotherapies generate immune cells that are effective killers of blood cancers, but they have a hard time with solid tumors.

16 Feb 2020

Research reveals novel way to treat cancers using CAR T cell therapy

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute at the University of Utah to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism.

10 Feb 2020

CRISPR-edited immune cells can be safely given to cancer patients

The emergence of CRISPR-Cas9 gene-editing technology has spurred hope in both doctors and patients since it shows promise in treating a multitude of diseases, including cancer. For the first time in the United States, a team of scientists has shown that CRISPR-edited immune cells can be safely used to cancer patients.

9 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

Researchers develop an emergency stop switch for CAR T-cell therapies

Immunotherapy, unlike chemotherapy and radiotherapy, arms the body's immune system to attack cancer cells. In recent years, it has proven to be remarkably successful at treating leukemia, lymphoma and other liquid cancers, or cancers present in body fluids.

4 Feb 2020

Ludwig Cancer Research study develops a safer CAR-T therapy

A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell-;a family of promising immunotherapies for cancer- that can be switched on and off on demand.

3 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

31 Jan 2020

Death receptor pathway drives resistance to CAR T cell therapy

Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why.

30 Jan 2020

Drug profiling and gene editing method open new avenues in the development of CAR T-cell therapy

Researchers have discovered ways to boost CAR T-cell therapy.

21 Jan 2020

Breakthrough discovery could lead to more effective immunotherapies

Scientists at UCL have discovered how immune cells, essential for tackling life-threatening infections and cancers, are able to 'recycle' material within themselves in order to stay healthy and function, a breakthrough finding which could lead to more effective immunotherapies.

21 Jan 2020

Study demonstrates striking improvements in bone marrow transplants since mid-2000s

A bone marrow transplant can be a lifesaving treatment, but it can come with life-threatening risks.

20 Jan 2020

Lab-grown brain organoids may hold the answers to personalized treatments for glioblastomas

Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.

26 Dec 2019

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

New approach can improve the activity of CAR-T cells against blood and solid cancers

A new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human cancer cells grown in the laboratory and in mice, according to a study by researchers at the Stanford University School of Medicine.

5 Dec 2019

New partnership aims to explore, cultivate innovations in cell and gene therapy

Some patients who have not responded to traditional medicines are now experiencing remarkable recoveries thanks to next-generation immunotherapies. These therapies equip a patient's own immune cells to recognize, target, and destroy cancer cells.

25 Nov 2019